Nasdaq wraps up Q3 with IPO pitches from Gamida Cell, NGM, Arog totalling $219M
Nasdaq’s bubbling biotech week did not just end with Gristone’s top-of-the-range raise, which brought the IPO tally to $520 million. Late Friday, three more biotechs lined up to enter the club, seeking a collective $219 million to fuel mid- and late-stage endeavors on cancer and NASH.
As we enter Q4, it remains to be seen whether 2018 — at 49 completed deals — will surpass the 66 biopharma IPO record set in 2014. But it is within range.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
